Nonetheless, diversified clinical samples should be further added to increase supportive evidence for the possibility of RFX3-AS1 in the diagnosis of NSCLC, and the regulatory effect of the RFX3-AS1-miR-577-STAT3 axis needs to be confirmed in more animal experiments. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.